Announced biosimilar manufacturing partnership using AI

Sandoz and Just – Evotec Biologics have announced a partnership to develop and manufacture multiple biosimilars. The agreement gives Sandoz access to an artificial intelligence (AI)-driven technology platform that enables fully integrated drug substance development and continuous manufacturing. This will help Sandoz expand its pipeline to 24 biosimilar assets.

AI-powered biosimilar manufacturing

According to Sandoz CEO Richard Sayner, as part of the strategic partnership, the companies will “leverage disruptive technologies at lower operating costs to bring high-quality biosimilars to patients around the world at scale. It is said that they share the commitment to

“By using these technologies to enhance and reduce the footprint of our manufacturing facilities, we can reduce production costs,” said Randal Bass, vice president of process design and biologics operations at Just – Evotec Biologics. , explained in a video published on the company’s Twitter page.

Continuous manufacturing of biologics

The partnership gives Sandoz the option to use Evotech Biologics’ advanced continuous manufacturing processes. This state-of-the-art drug development and manufacturing technology improves the quality and productivity of biologics production.

The deal “provides additional capabilities to support the strategic expansion of the pipeline with new assets and to begin transitioning the early biosimilar pipeline immediately, as Sandoz completes its planned separation from Novartis.” Until then, development and manufacturing continuity will be ensured.” Biosimilar development will be ramped up over the next 12 to 18 months,” Sandoz’s CEO said.

Sandoz Boosts Biosimilar Development with Manufacturing Expansion